Biotech and Medical Venture Deals Roundup
by Adam Rubenstein
OnBioVC
Calistoga (Seattle, WA) a spinout of Icos, is developing compounds targeting p110 delta for cancer, inflammatory and autoimmune indications raised $21M in a series A round. The financing was led by Frazier Healthcare Ventures and Alta Partners and joined by Three Arch Partners and Amgen Ventures.
BiPar (Brisbane, CA) an oncology company focused upon the use of PARP inhibitors and iodothyronine raised a $35M series B round. The deal was led by Domain Associates and joined by Vulcan Capital, Canaan Partners, PolyTechnos Asset Management and Quantum Technology Partners.
Microbia (Cambridge, MA) rational drug designer focused on GI and cardiovascular therapeutics raised a $50M series F round. The financing was led by Ridgeback Capital and joined by Morgan Stanley Investment Management.
PREVIOUS VENTURE DEAL ROUNDUPS:
- March 03, 2007
- February 24, 2007
____________________
OnBioVC
Calistoga (Seattle, WA) a spinout of Icos, is developing compounds targeting p110 delta for cancer, inflammatory and autoimmune indications raised $21M in a series A round. The financing was led by Frazier Healthcare Ventures and Alta Partners and joined by Three Arch Partners and Amgen Ventures.
BiPar (Brisbane, CA) an oncology company focused upon the use of PARP inhibitors and iodothyronine raised a $35M series B round. The deal was led by Domain Associates and joined by Vulcan Capital, Canaan Partners, PolyTechnos Asset Management and Quantum Technology Partners.
Microbia (Cambridge, MA) rational drug designer focused on GI and cardiovascular therapeutics raised a $50M series F round. The financing was led by Ridgeback Capital and joined by Morgan Stanley Investment Management.
PREVIOUS VENTURE DEAL ROUNDUPS:
- March 03, 2007
- February 24, 2007
____________________
posted by Nico at
9:32 AM
0 Comments:
Post a Comment
Subscribe to Post Comments [Atom]
<< Home